» Articles » PMID: 36142413

Combined PARP and Dual Topoisomerase Inhibition Potentiates Genome Instability and Cell Death in Ovarian Cancer

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 Sep 23
PMID 36142413
Authors
Affiliations
Soon will be listed here.
Abstract

Although ovarian cancer is a rare disease, it constitutes the fifth leading cause of cancer death among women. It is of major importance to develop new therapeutic strategies to improve survival. Combining P8-D6, a novel dual topoisomerase inhibitor with exceptional anti-tumoral properties in ovarian cancer and compounds in preclinical research, and olaparib, a PARP inhibitor targeting DNA damage repair, is a promising approach. P8-D6 induces DNA damage that can be repaired by base excision repair or homologous recombination in which PARP plays a major role. This study analyzed benefits of combining P8-D6 and olaparib treatment in 2D and 3D cultures with ovarian cancer cells. Measurement of viability, cytotoxicity and caspase activity were used to assess therapy efficacy and to calculate the combination index (CI). Further DNA damage was quantified using the biomarkers RAD51 and γH2A.X. The combinational treatment led to an increased caspase activity and reduced viability. CI values partially show synergisms in combinations at 100 nM and 500 nM P8-D6. More DNA damage accumulated, and spheroids lost their membrane integrity due to the combinational treatment. While maintaining the same therapy efficacy as single-drug therapy, doses of P8-D6 and olaparib can be reduced in combinational treatments. Synergisms can be seen in some tested combinations. In summary, the combination therapy indicates benefits and acts synergistic at 100 nM and 500 nM P8-D6.

Citing Articles

Evaluation of chronic drug-induced electrophysiological and cytotoxic effects using human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs).

Altrocchi C, Van Ammel K, Steemans M, Kreir M, Tekle F, Teisman A Front Pharmacol. 2023; 14:1229960.

PMID: 37492082 PMC: 10364322. DOI: 10.3389/fphar.2023.1229960.


Transcriptomic Analysis of CRISPR/Cas9-Mediated PARP1-Knockout Cells under the Influence of Topotecan and TDP1 Inhibitor.

Dyrkheeva N, Malakhova A, Zakharenko A, Okorokova L, Shtokalo D, Pavlova S Int J Mol Sci. 2023; 24(6).

PMID: 36982223 PMC: 10049738. DOI: 10.3390/ijms24065148.


The Implication of Topoisomerase II Inhibitors in Synthetic Lethality for Cancer Therapy.

Matias-Barrios V, Dong X Pharmaceuticals (Basel). 2023; 16(1).

PMID: 36678591 PMC: 9866718. DOI: 10.3390/ph16010094.

References
1.
Ledermann J . First-line treatment of ovarian cancer: questions and controversies to address. Ther Adv Med Oncol. 2018; 10:1758835918768232. PMC: 5898654. DOI: 10.1177/1758835918768232. View

2.
Deweese J, Osheroff N . The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing. Nucleic Acids Res. 2008; 37(3):738-48. PMC: 2647315. DOI: 10.1093/nar/gkn937. View

3.
Ray Chaudhuri A, Nussenzweig A . The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat Rev Mol Cell Biol. 2017; 18(10):610-621. PMC: 6591728. DOI: 10.1038/nrm.2017.53. View

4.
Das B, Huang S, Murai J, Rehman I, Ame J, Sengupta S . PARP1-TDP1 coupling for the repair of topoisomerase I-induced DNA damage. Nucleic Acids Res. 2014; 42(7):4435-49. PMC: 3985661. DOI: 10.1093/nar/gku088. View

5.
Tahara M, Inoue T, Sato F, Miyakura Y, Horie H, Yasuda Y . The use of Olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-mediated repair of DNA double-strand breaks. Mol Cancer Ther. 2014; 13(5):1170-80. DOI: 10.1158/1535-7163.MCT-13-0683. View